Molecular Imaging and Therapeutics Clinical Trials
18-FLT PET/MR Imaging to Predict Graft Failure and Graft Versus Host Disease in Bone Marrow Transplant Patients (PI: Yeuh Lee)
Purpose: This is a non-randomized, prospective pilot study exploring the use of fluorothymidine (FLT)-PET-MRI in the evaluation of allogeneic bone marrow transplant patients to potentially predict engraftment success, malignancy relapse, and the development of graft versus host.
Participants: A total of 12 patients who have undergone allogeneic bone marrow transplantation will undergo FLT-PET-MRI imaging on two separate occasions. In addition to the 12 allogenetic transplant patients, 3 patients undergoing autologous stem cell transplant will also be imaged imaged at the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
Procedures (methods): Patients who have undergone either allogenic or autologous bone marrow transplants will undergo FLT-PET-MRI imagining on two seperate occasions. The first scan will occur immediately after initial neutrophil count recovery on day +25. The second scan will occur on transplant day +60 by which time stable count recovery should have occured.
Hybrid Positron Emission Tomography-Magnetic Resonance (PET/MR) Imaging for Cervical Cancer (PI: Jorge Oldan)
Purpose: Both PET and MRI have a role in the initial workup of patients diagnosed with cervical cancer. The purpose of this study is to assess the feasibility of hybrid PET/MR for imaging of patients with newly diagnosed cervical cancer and to compare hybrid PET/MR imaging to standard workup with PET/CT.
Participants: Women with newly diagnosed invasive cervical cancer undergoing definitive treatment (surgery and/or radiation therapy)
Procedures (methods): Patients with newly diagnosed cervical cancer seeking consultation at UNC will be consented and enrolled. Patients will receive the standard workup and staging as determined by the treating gynecologic or radiation oncologist. Patients will typically undergo contrasted PET/CT scan as part of routine staging. The day following PET/CT, patients will undergo hybrid PET/MR. Both scans will take place immediately prior to initiation of definitive treatment in the form of either surgery or chemoradiation therapy.